{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:18:33Z","timestamp":1793161113653,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG So 328\/15-1"],"award-info":[{"award-number":["DFG So 328\/15-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG KO 4604\/2-1"],"award-info":[{"award-number":["DFG KO 4604\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Bortezomib (BTZ) is a selective and reversible proteasome inhibitor and first line treatment for multiple myeloma (MM). One of the side effects is BTZ-induced peripheral neuropathy (BIPN). Until now there is no biomarker which can predict this side effect and its severity. Neurofilament light chain (NfL) is a neuron specific cytoskeletal protein, of which higher levels can be detected in peripheral blood in case of axon damage. In this study, we aimed to evaluate the relationship between NfL serum levels and characteristics of BIPN.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a first interim analysis of a monocentric, non-randomized, observational clinical trial including 70 patients (DRKS00025422) diagnosed with MM in the inclusion period of June 2021 until March 2022. Two groups of patients\u2014one with ongoing BTZ treatment at the time of recruiting, and one with BTZ treatment in the past\u2014were compared to controls. NfL in serum was analyzed via the ELLA\u2122 device.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Both patients with previous and ongoing BTZ treatment had higher serum NfL levels than controls, and patients with ongoing BTZ treatment had higher NfL levels than patients with BTZ treatment in the past. Serum NfL levels correlated with electrophysiological measures of axonal damage in the group with ongoing BTZ treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Elevated NfL levels indicate acute axonal damage under BTZ in MM patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-023-11624-2","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T19:41:01Z","timestamp":1676835661000},"page":"2997-3007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-2281","authenticated-orcid":false,"given":"Nadine","family":"Cebulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Runau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Gommersbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Stengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kristin","family":"Reinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Rogalla von Bieberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Rittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,18]]},"reference":[{"key":"11624_CR1","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00108-013-3336-2","volume":"54","author":"KM Kort\u00fcm","year":"2013","unstructured":"Kort\u00fcm KM, Engelhardt M, Rasche L, Knop S, Einsele H (2013) Das multiple myelom. Der Internist 54:963\u2013977","journal-title":"Der Internist"},{"key":"11624_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","volume":"58","author":"CRC Tan","year":"2019","unstructured":"Tan CRC, Abdul-Majeed S, Cael B, Barta SK (2019) Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin Pharmacokinet 58:157\u2013168","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"11624_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0305-7372(03)00082-3","volume":"29","author":"HJ Lenz","year":"2003","unstructured":"Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29(Suppl 1):41\u201348","journal-title":"Cancer Treat Rev"},{"key":"11624_CR4","first-page":"6316","volume":"9","author":"PM Voorhees","year":"2003","unstructured":"Voorhees PM, Dees EC, O\u2019Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316\u20136325","journal-title":"Clin Cancer Res"},{"key":"11624_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12:431\u2013440","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"11624_CR6","first-page":"S52","volume":"24","author":"R Velasco","year":"2019","unstructured":"Velasco R, Alberti P, Bruna J, Psimaras D, Argyriou AA (2019) Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S52-s62","journal-title":"J Peripher Nerv Syst"},{"key":"11624_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/BLCTT.S91251","volume":"6","author":"S Grammatico","year":"2016","unstructured":"Grammatico S, Cesini L, Petrucci MT (2016) Managing treatment-related peripheral neuropathy in patients with multiple myeloma. Blood Lymphat Cancer 6:37\u201347","journal-title":"Blood Lymphat Cancer"},{"key":"11624_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","volume":"204","author":"G Cavaletti","year":"2007","unstructured":"Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D\u2019Incalci M, De Coster R (2007) Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 204:317\u2013325","journal-title":"Exp Neurol"},{"key":"11624_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ejpain.2009.07.001","volume":"14","author":"C Meregalli","year":"2010","unstructured":"Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L, Marmiroli P, Cavaletti G (2010) Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 14:343\u2013350","journal-title":"Eur J Pain"},{"key":"11624_CR10","doi-asserted-by":"crossref","unstructured":"Geisler S, Doan RA, Cheng GC, Cetinkaya-Fisgin A, Huang SX, H\u00f6ke A, Milbrandt J, DiAntonio A (2019) Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program. JCI Insight 4","DOI":"10.1172\/jci.insight.129920"},{"key":"11624_CR11","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","volume":"88","author":"AA Argyriou","year":"2014","unstructured":"Argyriou AA, Cavaletti G, Bruna J, Kyritsis AP, Kalofonos HP (2014) Bortezomib-induced peripheral neurotoxicity: an update. Arch Toxicol 88:1669\u20131679","journal-title":"Arch Toxicol"},{"key":"11624_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12035-008-8033-0","volume":"38","author":"R Perrot","year":"2008","unstructured":"Perrot R, Berges R, Bocquet A, Eyer J (2008) Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol 38:27\u201365","journal-title":"Mol Neurobiol"},{"key":"11624_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.expneurol.2018.06.005","volume":"307","author":"C Meregalli","year":"2018","unstructured":"Meregalli C, Fumagalli G, Alberti P, Canta A, Carozzi VA, Chiorazzi A, Monza L, Pozzi E, Sandelius \u00c5, Blennow K, Zetterberg H, Marmiroli P, Cavaletti G (2018) Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Exp Neurol 307:129\u2013132","journal-title":"Exp Neurol"},{"key":"11624_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/brainsci10010056","volume":"10","author":"KL Lambertsen","year":"2020","unstructured":"Lambertsen KL, Soares CB, Gaist D, Nielsen HH (2020) Neurofilaments: the C-reactive protein of neurology. Brain Sci 10:56","journal-title":"Brain Sci"},{"key":"11624_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Sch\u00e4delin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81:857\u2013870","journal-title":"Ann Neurol"},{"key":"11624_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jns.12493","volume":"27","author":"S Karteri","year":"2022","unstructured":"Karteri S, Bruna J, Argyriou AA, Mariotto S, Velasco R, Alemany M, Kalofonou F, Alberti P, Dinoto A, Velissaris D, Stradella A, Cavaletti G, Ferrari S, Kalofonos HP (2022) Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. J Peripher Nerv Syst 27:166\u2013174","journal-title":"J Peripher Nerv Syst"},{"key":"11624_CR17","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-548","journal-title":"Lancet Oncol"},{"key":"11624_CR18","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1136\/jnnp.72.5.596","volume":"72","author":"IS Merkies","year":"2002","unstructured":"Merkies IS, Schmitz PI, van der Mech\u00e9 FG, Samijn JP, van Doorn PA (2002) Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72:596\u2013601","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11624_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1471-2377-11-104","volume":"11","author":"C Sommer","year":"2011","unstructured":"Sommer C, Richter H, Rogausch JP, Frettl\u00f6h J, Lungenhausen M, Maier C (2011) A modified score to identify and discriminate neuropathic pain: a study on the German version of the neuropathic pain symptom inventory (NPSI). BMC Neurol 11:104","journal-title":"BMC Neurol"},{"key":"11624_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.pain.2006.01.041","volume":"123","author":"R Rolke","year":"2006","unstructured":"Rolke R, Baron R, Maier C, T\u00f6lle TR, Treede DR, Beyer A, Binder A, Birbaumer N, Birklein F, B\u00f6tef\u00fcr IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maih\u00f6fner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B (2006) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123:231\u2013243","journal-title":"Pain"},{"key":"11624_CR21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.pain.2010.07.026","volume":"151","author":"W Magerl","year":"2010","unstructured":"Magerl W, Krumova EK, Baron R, T\u00f6lle T, Treede RD, Maier C (2010) Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain 151:598\u2013605","journal-title":"Pain"},{"key":"11624_CR22","volume-title":"Electrodiagnosis in diseases of nerve and muscle: principles and practice","author":"J Kimura","year":"2001","unstructured":"Kimura J (2001) Electrodiagnosis in diseases of nerve and muscle: principles and practice, 3rd edn. Oxford University Press, Oxford","edition":"3"},{"key":"11624_CR23","unstructured":"International J-C Velcade\u00ae (Bortezomib) [SmPC], Beerse, Belgium: Janssen-Cilag International NV; (2021)"},{"issue":"Suppl 4","key":"11624_CR24","doi-asserted-by":"publisher","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","volume":"14","author":"W Grisold","year":"2012","unstructured":"Grisold W, Cavaletti G, Windebank AJ (2012) Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 14(Suppl 4):iv45-54","journal-title":"Neuro Oncol"},{"key":"11624_CR25","doi-asserted-by":"publisher","first-page":"7995","DOI":"10.1038\/s41598-020-64511-5","volume":"10","author":"SH Kim","year":"2020","unstructured":"Kim SH, Choi MK, Park NY, Hyun JW, Lee MY, Kim HJ, Jung SK, Cha Y (2020) Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 10:7995","journal-title":"Sci Rep"},{"key":"11624_CR26","doi-asserted-by":"publisher","first-page":"15593","DOI":"10.1038\/s41598-022-18716-5","volume":"12","author":"BL Burgess","year":"2022","unstructured":"Burgess BL, Cho E, Honigberg L (2022) Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. Sci Rep 12:15593","journal-title":"Sci Rep"},{"key":"11624_CR27","doi-asserted-by":"crossref","unstructured":"Huehnchen P, Schinke C, Bangemann N, Dordevic AD, Kern J, Maierhof SK, Hew L, Nolte L, K\u00f6rtvelyessy P, G\u00f6pfert JC, Ruprecht K, Somps CJ, Blohmer JU, Sehouli J, Endres M, Boehmerle W (2022) Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 7","DOI":"10.1172\/jci.insight.154395"},{"key":"11624_CR28","doi-asserted-by":"crossref","unstructured":"Mortensen C, Steffensen KD, Simonsen E, Herskind K, Madsen JS, Olsen DA, Iversen DB, Bergmann TK, Potteg\u00e5rd A, Stage TB (2022) Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer. Pain","DOI":"10.1097\/j.pain.0000000000002840"},{"key":"11624_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00415-022-11377-4","volume":"270","author":"R Velasco","year":"2023","unstructured":"Velasco R, Argyriou AA, Marco C, Mariotto S, Stradella A, Hern\u00e1ndez J, Pernas S, Ferrari S, Bruna J (2023) Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity. J Neurol 270:531\u2013537","journal-title":"J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11624-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T04:06:13Z","timestamp":1684209973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11624-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,18]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["11624"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11624-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,18]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CS is Deputy Editor of the \u201cEuropean Journal of Neurology\u201d, Associate Editor of \u201cPlosOne\u201d, \u201cNeurology Research and Practice\u201d and \u201cFortschritte der Neurologie und Psychiatrie\u201d. HR is Section Editor for \u201cPain Reports\u201d. DZ is member of the Editorial Board of \u201cKlinische Neurophysiologie\u201d and Review Editor at \u201cFrontiers in Neurology\u201d. CS has been a consultant for Merz, Omega, Ipsen and Bayer and has given educational talks for Amicus, GSK and Pfizer. DZ received compensation for participation on an advisory board of Biogen, as well as for consultancy work from Novartis. CS is immediate Past President of the International Association for the Study of Pain, Past President of Deutsche Schmerzgesellschaft and Board Member of the Peripheral Nerve Society. The other authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study has been approved by the Ethics Committee of the Medical Faculty of the University of W\u00fcrzburg (# 98\/20). After oral and written information, discussion, and a reflection period of at least 24\u00a0h, patients who agreed to participate signed the consent form and were thus included in the study. Controls for NfL detection in the serum were healthy volunteers without pain or other known neurological conditions (Ethics approval # 242\/17).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}